ProCE Banner Activity


NASH Core Curriculum: Emerging Management

Hear expert insights on emerging approaches for managing NASH, targeting both hepatic and extrahepatic manifestations.

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Nurses: 0.25 Nursing contact hour

Released: July 20, 2021

Expiration: July 19, 2022

No longer available for credit.



Stephen A. Harrison

Stephen A. Harrison, MD, MAJ (P), MC

Chief of Hepatology
Division of Gastroenterology and Hepatology
Brooke Army Medical Center
Fort Sam Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Novo Nordisk Inc



ProCE Banner

Target Audience

The online activities are intended for hepatologists, gastroenterologists, endocrinologists, and other physicians, nurses, pharmacists, and healthcare professionals who manage individuals with or at risk for NASH.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Critically evaluate the latest efficacy and safety data on emerging treatments for NASH, and their potential utility in NASH management


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Stephen A. Harrison, MD, MAJ (P), MC

Chief of Hepatology
Division of Gastroenterology and Hepatology
Brooke Army Medical Center
Fort Sam Houston, Texas

Stephen A. Harrison, MD, COL (Ret.), FAASLD, has disclosed that he has received consulting fees from Akero, Altimmune, Alentis, Axcella, Chronwell, CiVi Biopharma, Hepion, Echosens, Foresite Labs, Galectin, Genfit, Gilead Sciences, Hightide, HistoIndex, Inipharm, Intercept, Madrigal, Medpace, Metacrine, NGM Bio, NorthSea, Novartis, Novo Nordisk, PathAI, Poxel, Luminal, Terns, Viking, and Sagimet; has received funds for research support from Axcella, Bristol-Myers Squibb, Cirius, Conatus, Hepion, Cymabay, Enyo, Galectin, Galmed, Genfit, Gilead Sciences, Hightide, Immuron, Intercept, Madrigal, Metacrine, NGM Bio, NorthSea, Novartis, Novo Nordisk, Pfizer, Second Genome, Tobira/Allergan, and Sagimet; and has stock ownership or equity in Akero, Chronwell, Galectin, Genfit, HistoIndex, Madrigal, Metacrine, NGM, NorthSea and PathAI.

Staff Disclosure


Ruth Cohen,

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-131-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 20, 2021, through July 19, 2022:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this comprehensive program is to arm learners with foundational education in NASH pathogenesis, diagnosis, current recommended management, and emerging pharmacologic treatment strategies.